Henry Schein’s Q2 2026: Strong Sales, Stronger Guidance – A Patchwork of Momentum for HSIC

Lede: HSIC eyes the future with a steadier hand

Henry Schein, Inc. (Nasdaq: HSIC) posted its second-quarter 2026 results with a clear refrain: growth is real, and the roadmap ahead has a few more knobs to turn. The company reported EPS metrics that moved in the right direction and a revenue trajectory that nudged higher, even as currency swings and acquisitions continue to color the quarterly picture. In the language of earnings coverage, the release provides EPS and revenue forecast style data, while signaling that investors should watch for any earnings surprise versus EPS consensus as consensus estimates surface from analysts.

Key numbers at a glance

Company: Henry Schein, Inc. (Nasdaq: HSIC)
Quarter: Q2 2026
Total net sales: $3.5 billion, up 6.7% vs Q2 2025
Internal sales growth: 4.6%
Acquisitions: 0.7% contribution
Foreign currency impact: 1.4%
GAAP diluted EPS: $0.82 (Q2 2025: $0.70)
Non-GAAP diluted EPS: $1.27 (Q2 2025: $1.10)

Guidance and outlook: a prescription for growth

The company raised its full-year 2026 expectations. The revenue forecast now includes a non-GAAP diluted EPS target of $5.29 to $5.39, with Adjusted EBITDA growth framed as mid- to high-single digits and sales growth of roughly 4.5% to 5.5%.

In other words, the trajectory remains constructive: more of the same mix — steady internal growth, additive acquisitions, and a modest positive currency tailwind — all while the enterprise tightens its execution around margin and cash generation.

From the leadership: margins, momentum, and the road ahead

Fred Lowery, Chief Executive Officer of Henry Schein, highlighted that first-half performance and sustained momentum position the company to lift its FY2026 guidance. The press release quotes him describing strong earnings growth driven by momentum across the portfolio and solid operational execution. The tone suggests a focus not only on quarterly beat potential, but on the durability of the business model and the efficiency improvements from value creation initiatives.

What this could mean for HSIC’s sector peers

Henry Schein sits in a space where broad healthcare distribution competes with specialized segments and private-label import channels. The Q2 results reinforce a pattern of steady, diversified growth, where internal expansion helps offset ongoing integration of acquisitions and currency headwinds. For peers in global distribution and value-added services to dental and medical practitioners, the message is: discipline on margin, clarity on the growthdrivers (internal sales, acquisitions, and FX), and a credible plan to lift the revenue forecast and profitability in a careful, long-run way.

If the sector is pricing in a similar mix of volume growth and cost discipline, watch for how the competitive landscape handles a potential tightening of margins or shifting vendor dynamics. A few well-executed acquisitions can translate into outsized leverage, but only if the underlying demand remains durable and the integration work translates into real operating improvements.

A closer look at the quotes

"We delivered strong sales performance and margin improvement in the second quarter," said Fred Lowery, Chief Executive Officer of Henry Schein. "Our first-half performance and the sustained momentum have positioned us to raise our FY2026 guidance."

The language reads as a confidence signal—less about one-quarter’s surplus and more about a replicable, scalable growth engine. For investors monitoring EPS trajectories, the dual-track of GAAP and non-GAAP numbers provides a more complete view of how the business is translating top-line growth into bottom-line strength.

Takeaways for investors and analysts

HSIC’s Q2 results show resilience through a mix of internal growth and acquisitions, with a modest FX tailwind.
The EPS story is positive on both GAAP and non-GAAP lines, though analysts will compare these figures against EPS consensus estimates to judge any earnings surprise.
The raised revenue forecast and guidance for 2026 imply confidence in sustained demand from dental and medical practitioners and ongoing effectiveness of value creation initiatives.
Jurisdictional and currency considerations will remain a headwind or tailwind depending on the quarter; execution remains the key determinant of sustained margins.
Sector peers may respond by revisiting their own guidance and capacity to deploy acquisitions without sacrificing profitability.